A viatical settlement is a transaction in which a person with a terminal or chronic illness sells an existing life insurance policy to a third party. The seller, called the viator, receives a lump sum that is more than the policy's cash surrender value but less than its death benefit. The buyer becomes the owner and beneficiary, pays any remaining premiums and collects the full benefit from the insurer when the insured person dies.
The arrangement gives a seriously ill person money for medical care and living costs while still alive. For the buyer it is an investment whose return depends on how long the insured lives. The term is often used interchangeably with life settlement, but the two are usually distinguished: a life settlement involves an older policyholder who is not terminally ill. Both form part of the secondary market for life insurance.
How a viatical settlement works
The policyholder approaches a licensed settlement provider, often through a broker who seeks competing offers. The provider obtains the insured's medical records and commissions an estimate of life expectancy. Its offer is a discount to the face amount that reflects that estimate, the premiums still to be paid, the rating of the insurance company and the return the buyer requires. The shorter the life expectancy, the higher the share of the death benefit paid.
For example, a policy with a $200,000 death benefit and a cash surrender value of $15,000 might be sold for $130,000. The seller receives far more than a surrender would bring. The buyer earns $70,000, less premiums paid, if the benefit is collected as expected, and a lower annual return for every extra year the insured survives.
On closing, ownership and the beneficiary designation are transferred with the insurer's acknowledgement, and the money is normally paid through an escrow agent. Providers either hold policies themselves or resell them, whole or in fractional interests, to institutions and individual investors.
History
The word comes from the Latin viaticum, provisions for a journey. The business emerged in the United States in the late 1980s during the AIDS epidemic, when many young policyholders with short life expectancies and high medical bills had no other asset to draw on. The arrival of effective antiretroviral treatment in the mid-1990s lengthened lives sharply. That was a medical success and a financial loss for investors, whose returns fell as payouts were delayed and premiums continued. The industry then turned towards policies held by older people, creating the larger life settlement market.
Tax treatment and regulation in the United States
The Health Insurance Portability and Accountability Act of 1996 added section 101(g) to the Internal Revenue Code. Under it, the proceeds of a sale to a qualifying viatical settlement provider are generally excluded from the seller's federal taxable income when the insured is terminally ill, meaning a physician has certified that death is reasonably expected within 24 months. For a chronically ill insured the exclusion is limited and tied to the cost of long-term care. Details are published by the Internal Revenue Service (IRS).
Settlements are regulated mainly by state insurance departments. Most states license providers and brokers and require disclosures to sellers, including the alternatives available and the possible effect on creditors' claims and on eligibility for public benefits. Many laws follow a model act of the National Association of Insurance Commissioners, and they commonly bar the sale of a policy within a set period after it is issued.
Whether interests sold to investors are securities has been contested. A federal appeals court held in 1996, in a case brought by the Securities and Exchange Commission (SEC) against Life Partners, that they were not. Another appeals court reached the opposite conclusion in 2005 in the Mutual Benefits case, applying the Howey test. The SEC and state securities regulators treat fractional interests as securities, and settlements of variable life policies fall under the rules of the Financial Industry Regulatory Authority (FINRA).
Risks for investors
- Longevity. The return falls the longer the insured lives, and life expectancy estimates have often proved too short.
- Premiums. The policy lapses if premiums stop, so investors may face repeated calls for money.
- Illiquidity. There is no organised market in which an interest can readily be resold.
- Policy challenges. An insurer may contest a policy obtained by misstatement or bought without an insurable interest.
- Fraud. The sector has a record of abuses, including falsified medical histories, misleading life expectancy figures and promoters who paid earlier investors with new investors' money in the manner of a Ponzi scheme.
Alternatives for the policyholder
A sale is not the only way to release value. Many policies include an accelerated death benefit that lets a terminally ill insured draw part of the benefit directly from the insurer, usually at lower cost. A policy with cash value can support a loan or a withdrawal, and some lenders advance money against the death benefit. Regulators advise comparing these options, and the ethical and privacy implications of giving investors a financial interest in the seller's death, before agreeing to a settlement.